Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma

WHAT IS THIS SUMMARY ABOUT? This is a summary of a publication about the GMMG-CONCEPT study that was published in the Journal of Clinical Oncology in September 2023. The study tested if a combination of cancer drugs (isatuximab plus carfilzomib, lenalidomide, and dexamethasone, or Isa-KRd for short) was a safe treatment for people with high­risk newly diagnosed multiple myeloma. The GMMG-CONCEPT study included participants who had not been treated before and were eligible to receive a procedure called autologous stem cell transplant, as well as participants who were not eligible to receive transplants. HOW WAS THE STUDY IN THIS SUMMARY CONDUCTED? This report looked at a total of 125 participants; 99 were transplant-eligible and 26 were transplant-non-eligible. All participants were treated with Isa-KRd. The researchers measured the proportion of people who had ‘no detectable levels’ of myeloma cells in their body left while on treatment (called minimal residual disease negativity, or MRD negativity for short). The researchers measured the progression-free survival, or the average length of time it took between the participants joining the study until their cancer got worse or they died. The researchers also measured overall survival, which is the total amount of time people lived during the study, even if their cancer got worse. The researchers also monitored for side effects of Isa-KRd in all participants that received at least one treatment. WHAT WERE THE RESULTS OF THE STUDY? At the end of the consolidation therapy (intensified therapy that happens after initial therapy), MRD negativity was observed in the majority of transplant-eligible and transplant non-eligible patients. For many patients, this effect lasted 6 or more months. After more than 3 years in transplant eligible participants and 2 years and 9 months for transplant non-eligible participants, most participants were alive and their disease did not get worse. In both groups, the most common side effects of Isa-KRd treatment were low blood cell counts and infections. Overall, most of the side effects did not last long or were easily treated. WHAT WERE THE MAIN CONCLUSIONS REPORTED BY THE RESEARCHERS? In the GMMG-CONCEPT study, Isa-KRd treatment reduced the number of myeloma cells to no detectable levels in more than two thirds of the participants with high-risk newly diagnosed multiple myeloma. Clinical Trial Registration: NCT03104842 (ClinicalTrials.gov)

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2024-09-30
DOI
https://doi.org/10.1080/14796694.2024.2402639
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma

Lisa Leypoldt, Christoph Mann, Hermann Einsele, Maike de Wit et al.
Future Oncology
Multiple Myeloma Research and Treatments
article

Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma

Lisa Leypoldt, Christoph Mann, Hermann Einsele, Maike de Wit, Christof Scheid, Katja Christina Weisel, Axel Benner, Hans Christian Reinhardt, Annette Dieing, Markus Munder, Diana Tichy, Britta Besemer, Hartmut Goldschmidt, Mathias Hänel, Hans Salwender, Axel Nogai, Ullrich Graeven, Marc S. Raab, Manola Zago, Rudolf Peceny, Carsten Bokemeyer, Michael Hundemer, Ema Požek, Martin Görner, Peter Staib, Yon‐Dschun Ko, Anna Jauch
article en

Abstract

WHAT IS THIS SUMMARY ABOUT? This is a summary of a publication about the GMMG-CONCEPT study that was published in the Journal of Clinical Oncology in September 2023. The study tested if a combination of cancer drugs (isatuximab plus carfilzomib, lenalidomide, and dexamethasone, or Isa-KRd for short) was a safe treatment for people with high­risk newly diagnosed multiple myeloma. The GMMG-CONCEPT study included participants who had not been treated before and were eligible to receive a procedure called autologous stem cell transplant, as well as participants who were not eligible to receive transplants. HOW WAS THE STUDY IN THIS SUMMARY CONDUCTED? This report looked at a total of 125 participants; 99 were transplant-eligible and 26 were transplant-non-eligible. All participants were treated with Isa-KRd. The researchers measured the proportion of people who had ‘no detectable levels’ of myeloma cells in their body left while on treatment (called minimal residual disease negativity, or MRD negativity for short). The researchers measured the progression-free survival, or the average length of time it took between the participants joining the study until their cancer got worse or they died. The researchers also measured overall survival, which is the total amount of time people lived during the study, even if their cancer got worse. The researchers also monitored for side effects of Isa-KRd in all participants that received at least one treatment. WHAT WERE THE RESULTS OF THE STUDY? At the end of the consolidation therapy (intensified therapy that happens after initial therapy), MRD negativity was observed in the majority of transplant-eligible and transplant non-eligible patients. For many patients, this effect lasted 6 or more months. After more than 3 years in transplant eligible participants and 2 years and 9 months for transplant non-eligible participants, most participants were alive and their disease did not get worse. In both groups, the most common side effects of Isa-KRd treatment were low blood cell counts and infections. Overall, most of the side effects did not last long or were easily treated. WHAT WERE THE MAIN CONCLUSIONS REPORTED BY THE RESEARCHERS? In the GMMG-CONCEPT study, Isa-KRd treatment reduced the number of myeloma cells to no detectable levels in more than two thirds of the participants with high-risk newly diagnosed multiple myeloma. Clinical Trial Registration: NCT03104842 (ClinicalTrials.gov)

Future OncologyVol. 20(39)
Universität Hamburg (DE), Philipps University of Marburg (DE), German Cancer Research Center (DE), Johannes Gutenberg University Mainz (DE), Heidelberg University (DE), Universitätsklinikum Gießen und Marburg (DE), African Palliative Care Association (UG), Pallium India (IN), Virginia Cooperative Extension (US), University Hospital Heidelberg (DE), Humboldt-Universität zu Berlin (DE), Asklepios Klinik Altona (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), Cancer Research And Biostatistics (US), Kliniken Maria Hilf (DE), University Medical Center Hamburg-Eppendorf (DE), Vivantes Klinikum (DE), National Center for Tumor Diseases (DE), Palmetto Hematology Oncology (US), Sankt-Antonius-Hospital Eschweiler (DE), Essen University Hospital (DE), Asklepios Klinik St. Georg (DE), Bipar (FR), Mammazentrum Hamburg (DE), Universitätsklinikum Würzburg (DE), German National Bone Marrow Donor Registry (DE), Klinikum Bielefeld (DE), Institute of Immunology (HR), Klinikum Osnabrück (DE), Stem Cell Institute (PA), Hematology Oncology Associates (US), Johanniter-Krankenhaus Bonn (DE), University Hospital Cologne (DE), European Association for Palliative Care (BE), National Institute Of Blood Disease and Bone Marrow Transplantation (PK), Center for Rheumatology (US), Klinikum Chemnitz (DE), Deutsches Konsortium für Translationale Krebsforschung (DE), University of Duisburg-Essen (DE), Charité - Universitätsmedizin Berlin (DE), University of Tübingen (DE), Heidelberg University (US)
Amgen, Bristol-Myers Squibb, Sanofi, Celgene, Universitätsklinikum Hamburg-Eppendorf
Quality Education
Openalex Percentile: Top 73%
Multiple Myeloma Research and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.